Search

Search Constraints

You searched for: Author/Creator Brunetto, M.

Search Results

1. A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure. (8th October 2016)

2. Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data. (March 2023)

3. Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis. (March 2023)

5. HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study. (10th February 2016)

6. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study. (March 2023)

7. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing. Issue 1 (February 2018)

8. OC.01.6 THE CT1 MULTI-PARAMETRIC MRI VALUE IS MORE SENSITIVE AND RELIABLE THAN TRANSIENT ELASTOGRAPHY FOR THE NON-INVASIVE MONITORING OF INTRA-HEPATIC INFLAMMATION/FIBROSIS RESPONSE TO DAA THERAPY IN CHC PATIENTS. (25th March 2019)

9. Prediction of response to obeticholic acid in primary biliary cholangitis: Development and validation of the OCA response score (ORS). (March 2023)

10. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience. (February 2019)